ReviewPharmaceutics2019
Neuronanomedicine: An Up-to-Date Overview.
Review in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Nanotechnology in Improving the Treatment of Huntington's Disease: a Systematic Review.Neurotoxicity research · 2022Pooled it
- Neuroprotective role of cyanidin in Alzheimer's and Parkinson's disease: current insights and the road ahead.Inflammopharmacology · 2026Review
- Alzheimer's disease: unraveling role of xanthone derivatives and nanocarriers.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Nano-antioxidants for neurodegenerative disorders: a scoping review.Discover nano · 2025Review
- The blood-brain barriers: novel nanocarriers for central nervous system diseases.Journal of nanobiotechnology · 2025Review
- Metallic Nanoparticles Applications in Neurological Disorders: A Review.International journal of biomaterials · 2025Review
- Inorganic Nanoparticles-based Drug Delivery Systems for Neurodegenerative Diseases Therapy.Current pharmaceutical design · 2025Review
- PLGA-LEC/F127 hybrid nanoparticles loaded with curcumin and their modulatory effect on monocytes.Nanomedicine (London, England) · 2024Article
- Article
- How Precise are Nanomedicines in Overcoming the Blood-Brain Barrier? A Comprehensive Review of the Literature.International journal of nanomedicine · 2024Review
- Recent Advances in Nanoformulations for Quercetin Delivery.Pharmaceutics · 2023Review
- Energy Partitioning in Multicomponent Nanoscintillators for Enhanced Localized Radiotherapy.ACS applied materials & interfaces · 2023Article
- Graphene Oxide Nanosheets Reduce Astrocyte Reactivity to Inflammation and Ameliorate Experimental Autoimmune Encephalomyelitis.ACS nano · 2023Article
- Synthesis Optimization of BaGdFMaterials (Basel, Switzerland) · 2022Article
- New Strategies for Stroke Therapy: Nanoencapsulated Neuroglobin.Pharmaceutics · 2022Review
- Inorganic Nanomaterials versus Polymer-Based Nanoparticles for Overcoming Neurodegeneration.Nanomaterials (Basel, Switzerland) · 2022Review
- Blood-brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders.Molecular brain · 2022Review
- Dendrimers as Antiamyloid Agents.Pharmaceutics · 2022Review
- Review
- Dodging blood brain barrier with "nano" warriors: Novel strategy against ischemic stroke.Theranostics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The field of neuronanomedicine has recently emerged as the bridge between neurological sciences and nanotechnology. The possibilities of this novel perspective are promising for the diagnosis and treatment strategies of severe central nervous system disorders. Therefore, the development of nano-vehicles capable of permeating the blood⁻brain barrier (BBB) and reaching the brain parenchyma may lead to breakthrough therapies that could improve life expectancy and quality of the patients diagnosed with brain disorders. The aim of this review is to summarize the recently developed organic, inorganic, and biological nanocarriers that could be used for the delivery of imaging and therapeutic agents to the brain, as well as the latest studies on the use of nanomaterials in brain cancer, neurodegenerative diseases, and stroke. Additionally, the main challenges and limitations associated with the use of these nanocarriers are briefly presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.